Article

Prolonged COVID-19 Infection in a Patient with Multiple Sclerosis and Rituximab-Treatment

2021-04-28

Abstract excerpt

<title>Abstract</title> <p>We present a prolonged disease course in a 32-year old woman with COVID-19 and multiple sclerosis on rituximab-treatment for three years. The patient was admitted to the hospital for COVID-19 and had persistent fever, cough and radiologic bilateral lung opacities over the course of 29 days. After ineffective antibiotic treatment and the detection that she had no antibodies against SARS-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6eac48c7-03c8-5e9c-a2c8-13c95cc7be70
DOI: 10.21203/rs.3.rs-393010/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prolonged COVID-19 Infection in a Patient with Multiple Sclerosis and Rituximab-TreatmentDOI 10.21203/rs.3.rs-393010/v1Read

Long-standing COVID-19 disease in immunedeficient patients; case reports and literature reviewSemantic proximity Read

Disease Modifying Therapies and COVID-19 Severity in Multiple SclerosisSemantic proximity Read

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity Read

SARS-CoV-2 infection among patients with multiple sclerosis; A cross-sectional studySemantic proximity Read

Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapySemantic proximity Read

Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort StudySemantic proximity Read

Atypical COVID-19 dynamics in a patient with Mantle Cell Lymphoma Exposed to RituximabSemantic proximity Read

Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 VaccinationSemantic proximity Read

A case study: ADEM-like lesions as a first clinical event in highly active multiple sclerosisSemantic proximity Read

Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccinesSemantic proximity Read

COVID-19 Severity in Multiple Sclerosis: Putting Data Into ContextSemantic proximity Read

Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS RegistrySemantic proximity Read